H.C. Wainwright adjusted its financial outlook for PepGen Inc. (NASDAQ:PEPG), reducing the price target to $16.00 from the ...

This pharma stock has made strong gains over the past 12 months thanks to its strong earnings. Now it is testing a fresh buy ...

In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...

A Vancouver family is sending their son on one final journey into the stars, where his ashes will eventually transform into a ...

While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...

Columnist Betty Vertin has learned that as a parent, she's finding the years with all her children, including those with DMD, too short.

Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...

The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years ...

Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...

PepGen (PEPG) “provided recent updates on its CONNECT clinical program investigating PGN-EDO51 in Duchenne muscular dystrophy for patients ...

(RTTNews) - Sarepta Therapeutics, Inc. (SRPT) Monday reported positive topline results from Part 2 of the Phase 3 study, dubbed EMBARK, of its gene therapy Elevidys approved for the treatment of ...

Prophylactic cardiac treatment may prolong survival in Duchenne muscular dystrophy (DMD), but only one-quarter of individuals ...